UBS Initiates Ocular Therapeutix Coverage With Buy Rating
UBS began covering Ocular Therapeutix with a Buy rating and set a $14.00 per-share price target for the company’s stock.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires reports, citing Benzinga data, that UBS initiated coverage of Ocular Therapeutix with a Buy rating.
Benzinga said UBS set a price target of $14.00 per share for the company. The information was published on October 12, 2026, at 13:30 GMT.
why it matters
The UBS action adds a new analyst assessment of Ocular Therapeutix and may focus investor attention on OCUL shares.
instruments
sources
- Ocular Therapeutix Initiated at Buy by UBS — Dow Jones Newswires, 12 October 2026 at 13:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗